source
- Federal judge denies Novo's attempt to block Eli Lilly obesity drug adsA federal judge in the U.S. District Court denied Novo Nordisk's request to halt an Eli Lilly advertising campaign that compared the two companies' obesity treatments, Wegovy and Zepbound. Novo ar…
- Aspen Neuroscience and Bambusa Therapeutics each target $134 million IPOsAspen Neuroscience, a cell‑therapy company focused on Parkinson's disease, and Bambusa Therapeutics, a bispecific biotech, have filed SEC documents outlining plans for initial public offerings. Bo…